TY - JOUR
T1 - Laparoscopic Partial Splenectomy for Unknown Primary Cancer
T2 - A Stepwise Approach
AU - Vega, Eduardo A.
AU - Yamashita, Suguru
AU - Shin, Chun Yun
AU - Kim, Michael
AU - Fleming, Jason B.
AU - Katz, Mathew H.
AU - Raghav, Kanwal P.S.
AU - Vauthey, Jean Nicolas
AU - Lee, Jeffrey E.
AU - Conrad, Claudius
N1 - Publisher Copyright:
© 2016, Society of Surgical Oncology.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Background: Laparoscopic partial splenectomy (LPS) for focal splenic lesions is technically demanding and carries risk of hemorrhage. Nevertheless, it can be a valuable option, particularly for children and adults in whom attempt at preservation of splenic immunologic function outweighs risk associated with organ preservation. Patient: A 58-year-old man was diagnosed with a focal splenic lesion at the upper splenic pole on surveillance imaging following axillary lymph node metastasis for cancer of unknown primary origin (CUP). After an interval of 8 months, repeat FDG-PET showed increase in size and PET-avidity without any evidence of new lesions. Due to isolated site and history of CUP, the patient was considered for a LPS. Technique: With the patient in reversed modified French position, the upper pole splenic vessels were controlled and a well-defined area of ischemia encompassing the lesion identified. Under intermittent inflow occlusion and ultrasonography guidance, the parenchymal transection was performed. Total operative time was 180 min, estimated blood loss was 175 cc, the patient was discharged on postoperative day 2, and final pathology confirmed an Epstein-Barr virus associated inflammatory pseudotumor.1,2 Conclusion: Safe LPS requires systematic pre-operative assessment of hilar vascular anatomy and a stepwise approach to controlling the vessels intra-operatively. Anatomic parenchymal transection and intermitted vascular isolation for lesions close to the demarcation zone minimizes blood loss. Risk/benefit stratification of LPS may be beneficial in select patients only. Whether in patients with CUP LPS may aid in preserving innate and adaptive immunity with potential clinical, including oncologic, benefits will require further investigations.3–5
AB - Background: Laparoscopic partial splenectomy (LPS) for focal splenic lesions is technically demanding and carries risk of hemorrhage. Nevertheless, it can be a valuable option, particularly for children and adults in whom attempt at preservation of splenic immunologic function outweighs risk associated with organ preservation. Patient: A 58-year-old man was diagnosed with a focal splenic lesion at the upper splenic pole on surveillance imaging following axillary lymph node metastasis for cancer of unknown primary origin (CUP). After an interval of 8 months, repeat FDG-PET showed increase in size and PET-avidity without any evidence of new lesions. Due to isolated site and history of CUP, the patient was considered for a LPS. Technique: With the patient in reversed modified French position, the upper pole splenic vessels were controlled and a well-defined area of ischemia encompassing the lesion identified. Under intermittent inflow occlusion and ultrasonography guidance, the parenchymal transection was performed. Total operative time was 180 min, estimated blood loss was 175 cc, the patient was discharged on postoperative day 2, and final pathology confirmed an Epstein-Barr virus associated inflammatory pseudotumor.1,2 Conclusion: Safe LPS requires systematic pre-operative assessment of hilar vascular anatomy and a stepwise approach to controlling the vessels intra-operatively. Anatomic parenchymal transection and intermitted vascular isolation for lesions close to the demarcation zone minimizes blood loss. Risk/benefit stratification of LPS may be beneficial in select patients only. Whether in patients with CUP LPS may aid in preserving innate and adaptive immunity with potential clinical, including oncologic, benefits will require further investigations.3–5
UR - http://www.scopus.com/inward/record.url?scp=85004000412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85004000412&partnerID=8YFLogxK
U2 - 10.1245/s10434-016-5664-7
DO - 10.1245/s10434-016-5664-7
M3 - Article
C2 - 27942901
AN - SCOPUS:85004000412
SN - 1068-9265
VL - 24
SP - 1134
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 4
ER -